Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 2103

Next Previous
Drug Profile

TQB 2103

Alternative Names: TQB-2103

Latest Information Update: 07 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Jul 2023 TQB 2103 is available for licensing as of 07 Jul 2023. https://www.cttq.com/en/partner/index.htm; also company is subsidiary of Sino Biopharmaceutical
  • 04 Jul 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT05867563)
  • 22 May 2023 Chia Tai Tianqing Pharmaceutical plans a phase I trial for Cancer (Late-stage disease, Second line therapy or greater) in China (IV)(NCT05867563)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top